Business Context and Reporting Period
This Form 8-K, dated October 4, 2018, reports on Avista Healthcare Public Acquisition Corp. (AHPAC), a Cayman Islands exempted company and special purpose acquisition company (SPAC). The filing details the results of an Extraordinary General Meeting (EGM) held on October 4, 2018, regarding a proposed business combination with Organogenesis Inc.
Key Financial Metrics and Transaction Details
- Share Redemption: Holders of 30,798,019 Class A ordinary shares exercised their right to redeem shares.
- Redemption Price: Approximately $10.20 per share.
- Total Redemption Amount: Approximately $314,258,591.61.
- Voting Participation: 35,919,455 ordinary shares (97.57% of outstanding shares) were represented at the EGM.
- Trust Account Extension: The liquidation deadline for the trust account was extended from October 14, 2018, to February 15, 2019.
Material Changes and Voting Results
Shareholders approved two critical proposals to facilitate the proposed merger with Organogenesis:
- Extension Amendment Proposal: Approved to extend the deadline to consummate a business combination to February 15, 2019.
- For: 30,179,230 votes
- Against: 3,302,225 votes
- Abstain: 2,438,000 votes
- Trust Amendment Proposal: Approved to amend the Investment Management Trust Agreement to align the liquidation date with the new business combination deadline.
- For: 30,179,230 votes
- Against: 3,302,225 votes
- Abstain: 2,438,000 votes
The filing does not provide standard operating financial metrics such as revenue, profit, or cash flow, as AHPAC is a pre-merger SPAC holding funds in a trust account.
Outlook, Risks, and Management Commentary
The approval of the extension provides AHPAC with additional time to evaluate and consummate the business combination with Organogenesis, pursuant to a Merger Agreement dated August 17, 2018. The filing includes extensive forward-looking statements regarding the potential benefits of the combination, subject to risks including:
- Termination of the Merger Agreement.
- Failure to obtain necessary stockholder approvals or regulatory conditions.
- Inability to meet NASDAQ listing standards.
- Operational disruptions to Organogenesis during the transaction process.
- Competition and the ability to manage growth profitably post-merger.
Investors are advised to review the definitive Registration Statement on Form S-4 for detailed risk factors and financial projections.
Key Facts for Investor Verification
- Verify the final redemption amount and the remaining cash balance in the trust account post-redemption.
- Confirm the status of the Merger Agreement with Organogenesis and any conditions precedent to closing.
- Review the definitive Form S-4 Registration Statement for updated financial projections and risk factors.
- Monitor the timeline for the final shareholder vote on the business combination, as the extension only delays the liquidation deadline.
- Assess the impact of the significant share redemption ($314 million) on the capital structure of the combined entity.